The All Wales Medicines Strategy Group (AWMSG) has recommended Bayer Healthcare’s Sativex Oromucosal Spray for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS).

Sativex Oromucosal Spray, which is recommended by NHS Wales, UK, is derived from whole plant extracts from the cannabis sativa plant and contains both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

"The AWMSG’s recognition of the value of Sativex is a significant milestone for the treatment of spasticity."

Commenting on the recommendation, Neath Port Talbot Hospital Rehabilitation Medicine consultant Dr Sajida Javaid said: "The AWMSG’s recognition of the value of Sativex is a significant milestone for the treatment of spasticity.

"Improved access to Sativex has been long awaited by clinicians and patients since its launch in 2010, so it is encouraging to see that patients in Wales will now have improved access to a treatment that has been proven to provide significant relief from the spasms and cramps associated with spasticity."

AWMSG has recommended Sativex as a treatment for adult patients who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

The prescription-only Sativex has to be sprayed on to different sites of the oromucosal surface, changing the application site each time it is used, according to Bayer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sativex was shown to provide significant improvement in the 0-10 numeric rating scale (NRS) spasticity score and spasm frequency, compared with a placebo, in the phase III clinical trial.